阿司匹林一级预防与心血管及出血事件的关联:系统综述与荟萃分析
该系统综述与荟萃分析纳入13项随机临床试验、共164 225名无已知心血管疾病的受试者,评估阿司匹林一级预防与心血管事件及出血的关联。结果显示阿司匹林与复合心血管结局风险降低相关(HR 0.89),同时与主要出血风险升高相关(HR 1.43)。
要点
- 阿司匹林一级预防与复合心血管结局风险降低相关,HR 0.89。
- 阿司匹林与主要出血风险升高相关,HR 1.43。
- 需结合个体风险获益与患者讨论阿司匹林一级预防。
核心结论
- 在无心血管疾病的人群中,阿司匹林使用与较低的心血管事件风险和增加的主要出血风险相关。
- 该信息可用于与患者讨论阿司匹林用于心血管事件一级预防及出血问题。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase及Cochrane Library Central Register of Controlled Trials,截至2018年11月1日。
- 纳入标准为随机临床试验,样本量至少1000例、无已知心血管疾病、随访至少12个月,比较阿司匹林与不用阿司匹林(安慰剂或无治疗)。
- 共纳入13项试验,随机化164 225名受试者,随访1 050 511人年。
- 受试者中位年龄62岁(范围53-74),77 501人(47%)为男性,30 361人(19%)有糖尿病。
- 主要心血管结局的中位基线风险为9.2%(范围2.6%-15.9%)。
主要发现
- 阿司匹林组复合心血管结局为57.1/10 000人年,不用阿司匹林组为61.4/10 000人年(HR 0.89 [95%可信区间 0.84-0.95])。
- 复合心血管结局绝对风险降低0.38%(95% CI 0.20%-0.55%),需治疗人数为265。
- 阿司匹林组主要出血事件为23.1/10 000人年,不用阿司匹林组为16.4/10 000人年(HR 1.43 [95%可信区间 1.30-1.56])。
- 主要出血绝对风险增加0.47%(95% CI 0.34%-0.62%),需伤害人数为210。
关键数值与推荐
- 主要心血管结局为心血管死亡、非致死性心肌梗死和非致死性卒中的复合终点。
- 主要出血结局为任何主要出血(由各研究定义)。
临床怎么用
- 对于无心血管疾病者,使用阿司匹林一级预防需权衡心血管事件减少与主要出血风险增加。
- 该荟萃分析结果可用于与患者讨论阿司匹林一级预防的获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk. OBJECTIVE: To assess the association of aspirin use for primary prevention with cardiovascular events and bleeding. DATA SOURCES: PubMed and Embase were searched on Cochrane Library Central Register of Controlled Trials from the earliest available date through November 1, 2018. STUDY SELECTION: Randomized clinical trials enrolling at least 1000 participants with no known cardiovascular disease and a follow-up of at least 12 months were included. Included studies compared aspirin use with no aspirin (placebo or no treatment). DATA EXTRACTION AND SYNTHESIS: Data were screened and extracted independently by both investigators. Bayesian and frequentist meta-analyses were performed. MAIN OUTCOMES AND MEASURES: The primary cardiovascular outcome was a composite of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke. The primary bleeding outcome was any major bleeding (defined by the individual studies). RESULTS: A total of 13 trials randomizing 164 225 participants with 1 050 511 participant-years of follow-up were included. The median age of trial participants was 62 years (range, 53-74), 77 501 (47%) were men, 30 361 (19%) had diabetes, and the median baseline risk of the primary cardiovascular outcome was 9.2% (range, 2.6%-15.9%). Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio [HR], 0.89 [95% credible interval, 0.84-0.95]; absolute risk reduction, 0.38% [95% CI, 0.20%-0.55%]; number needed to treat, 265). Aspirin use was associated with an increased risk of major bleeding events compared with no aspirin (23.1 per 10 000 participant-years with aspirin and 16.4 per 10 000 participant-years with no aspirin) (HR, 1.43 [95% credible interval, 1.30-1.56]; absolute risk increase, 0.47% [95% CI, 0.34%-0.62%]; number needed to harm, 210). CONCLUSIONS AND RELEVANCE: The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.
引用
- Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA. 2019. PMID: 30667501. doi:10.1001/jama.2018.20578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。